Subsequent Events	9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below. Subsequent to September 30, 2024, the Company received gross proceeds of $300,000 from investors in connection with the issuance of an aggregate of 39,997 shares of its Series B Convertible Preferred Stock and five-year warrants to purchase an aggregate of 450,000 shares of the Company’s common stock at an exercise price of $0.75 per share. Subsequent to September 30, 2024, the Company received gross proceeds of $75,000 from investors in connection with the issuance of an aggregate of 214,287 shares of its Common Stock and ten-year warrants to purchase an aggregate of 214,287 shares of the Company’s common stock at an exercise price of $0.35 per share. Subsequent to September 30, 2024, the Company entered into note amendment agreements with a trust controlled by Darlene Soave to extend the maturity dates of a note originally issued to Ms. Soave and assigned to the trust and the Verstraete Note, which had an outstanding principal amount of $3,736,708 as of September 30, 2024, to April 28, 2025 and March 10, 2025, respectively.

Subsequent Events

9 Months Ended

Sep. 30, 2024

Note 10 – Subsequent Events

The Company has evaluated events that have occurred after the balance sheet and through the date the financial statements were issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements, except as disclosed below.

Subsequent to September 30, 2024, the Company received gross proceeds of $300,000 from investors in connection with the issuance of an aggregate of 39,997 shares of its Series B Convertible Preferred Stock and five-year warrants to purchase an aggregate of 450,000 shares of the Company’s common stock at an exercise price of $0.75 per share.

Subsequent to September 30, 2024, the Company received gross proceeds of $75,000 from investors in connection with the issuance of an aggregate of 214,287 shares of its Common Stock and ten-year warrants to purchase an aggregate of 214,287 shares of the Company’s common stock at an exercise price of $0.35 per share.

Subsequent to September 30, 2024, the Company entered into note amendment agreements with a trust controlled by Darlene Soave to extend the maturity dates of a note originally issued to Ms. Soave and assigned to the trust and the Verstraete Note, which had an outstanding principal amount of $3,736,708 as of September 30, 2024, to April 28, 2025 and March 10, 2025, respectively.